Comment by 3eb7988a1663

Never heard the follow-up, so good to hear that it was potentially less hazardous than the initial reporting.

However, I am still mixed on the interpretation. I do not think the FDA is as good as say the NTSB, but I do think they will take lessons learned from a bad outcome. New medical products are likely to undergo additional scrutiny on any kinds of foams/solvents/whatever that are directly in the airway path. It is only because it is such a heavily regulated product that the entire product chain had to be stamped, certified, and traced so that such an investigation was possible. In a theoretical fly-by-night product offering, SKUs might be changing daily as the vendor can shave pennies off of the development price.